Boston Scientific/RadioTherapeutics
This article was originally published in The Gray Sheet
Executive Summary
Firms forge a strategic alliance whereby Boston Scientific picks up exclusive marketing and distribution rights in Japan and in interventional radiology and other markets in the U.S. to RadioTherapeutics' radiofrequency-based products. Approved in the U.S. for use in soft tissue necrosis, the minimally invasive RF systems, which include the Leveen needle electrode, are being evaluated in ongoing clinical studies for metastatic liver tumor ablation. As part of the agreement, Boston Scientific is making a "substantial" equity investment in the Mountain View, California-based company